shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Notice of Intent to Publish a Funding Opportunity Announcement for Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT)- Lung Cancer Screening (UG3/UH

    NOT-CA-24-075

    Opening date 19 Jul 2024, 12:00AM

    Closing date N/A

    Funding Opportunity Number: NOT-CA-24-075

    Opportunity Category: Discretionary

    Expected Number of Awards: 3

    CFDA Number(s): 93.393 -- Cancer Cause and Prevention Research

    Cost Sharing or Matching Requirement: No

    Posted Date: Jul 19, 2024 12:00:00 AM EDT

    Closing Date: N/A

    Estimated Total Program Funding: 2400000

    Eligible Applicants: State governments,Others (see text field entitled "Additional Information on Eligibility" for clarification),For profit organizations other than small businesses,Native American tribal governments (Federally recognized),Small businesses,Private institutions of higher education,Public and State controlled institutions of higher education,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,County governments,Public housing authorities/Indian housing authorities,Independent school districts,Native American tribal organizations (other than Federally recognized tribal governments)

    Description: The National Cancer Institute (NCI) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to the Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) Lung Cancer Screening (LCS) initiative. Up to three (3) Research Projects are expected to be funded as part of SUMMIT LCS initiative. Each Research Project will advance the science of scale-up and sustainment by testing strategies to increase and sustain the delivery of high-quality guideline concordant LCS among populations at high-risk for lung cancer. The NOFO is expected to use the UG3/UH3 Exploratory/Developmental Cooperative Agreement activity code with the Clinical Trials Required designation. Awards made under this NOFO will initially support a two-year maximum milestone driven UG3 phase with a possible transition to a four-year maximum UH3 phase. During the UG3 phase, scale-up and sustainment strategies will be refined and preparatory activities for the scale-up and sustainment trial will occur. NCI will conduct an administrative review of UG3 milestones. Projects that do not complete UG3 milestones will not be approved to move forward to the UH3 phase. The scale-up and sustainment trial will be conducted during the UH3 phase. The NOFO is expected to be published in late Summer 2024 with an expected application due date in late Fall 2024. Details of a pre-application webinar will be announced after the publication of the NOFO. This Notice is being provided to allow sufficient time for potential applicants with relevant expertise and insights to consider applying for this NOFO. Potential applicants are encouraged to view the presentation of this initiative to the Joint Virtual Meeting of the NCI Board of Scientific Advisors and the National Cancer Advisory Board available at https://videocast.nih.gov/watch=54859 beginning at 3 hour, 57 minutes. Presentation slides are downloadable at https://deainfo.nci.nih.gov/advisory/joint/0624/Chambers.pdf. � �

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept